CN103189041A - Composition for promoting fingernail or toenail growth - Google Patents
Composition for promoting fingernail or toenail growth Download PDFInfo
- Publication number
- CN103189041A CN103189041A CN2011800534944A CN201180053494A CN103189041A CN 103189041 A CN103189041 A CN 103189041A CN 2011800534944 A CN2011800534944 A CN 2011800534944A CN 201180053494 A CN201180053494 A CN 201180053494A CN 103189041 A CN103189041 A CN 103189041A
- Authority
- CN
- China
- Prior art keywords
- fingernail
- toenail
- composition
- growth
- promoting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a composition for promoting fingernail or toenail growth, containing valproic acid or a pharmaceutically acceptable salt as an active ingredient. In addition, disclosed are pharmaceutical and cosmetic compositions containing the composition.
Description
Technical field
The present invention relates to fingernail or toenail growth composition for promoting.
Background technology
Fingernail and toenail are respectively the hard and thin tablets that is attached to finger or toe end, are to be changed by keratodermatitis.The main constituent of fingernail and toenail is to be called keratic protein, and during known increase protein uptake amount, the speed of growth of fingernail and toenail is accelerated.
Usually the speed of growth of fingernail is faster than toenail, and it is centrifugal dirty near according to fingernail is arranged, thereby the fast saying of blood circulation and the saying that is subjected to many relatively stimulations, but does not also open correct reason.In addition, known modern's fingernail and the speed of growth of toenail are compared ever-faster, and this is proposed owing to be that the modern absorbs the basis due to the more protein.
Summary of the invention
The invention provides fingernail or toenail growth composition for promoting.In addition, also provide the growth of fingernail or toenail to promote pharmaceutical composition or cosmetic composition.
One aspect of the present invention provides a kind of fingernail or toenail growth composition for promoting, wherein, comprises valproic acid or its salt that pharmaceutically allows as effective ingredient.
The present invention provides a kind of pharmaceutical composition on the other hand, wherein, contains and comprises described valproic acid or its salt that pharmaceutically allows as the compositions of effective ingredient.
In addition, another aspect of the invention provides a kind of cosmetic composition, wherein, contains and comprises described valproic acid or its salt that pharmaceutically allows as the compositions of effective ingredient.
Compositions according to an aspect of the present invention comprises valproic acid or its salt that pharmaceutically allows as effective ingredient, thereby can promote the growth of fingernail or toenail.Described compositions not only can be used normal object needs the situation of growth of promotion fingernail or toenail owing to the reason aspect the beauty treatment etc. under, can also be owing to during the poor growth of the fingernail of fingernail or toenail disease and object or toenail, use with the purposes that promotes its growth.As mentioned above, can promote to suffer from the fingernail of object of fingernail or toenail disease or the growth of toenail, thereby can shorten during fingernail or the toenail treatment of diseases, improve therapeutic effect.
Description of drawings
Fig. 1 be expression before be coated with (0 day) to coating after 10 days (10 days) and from before being coated with to coating grow chart of length of the fingernail of the experimental group (left side) of (20 days) and matched group (right side) after 20 days.
Fig. 2 is the photo of representing according to the fingernail extent of growth of coating time, and a is the fingernail photo before the coating, and b is the fingernail photo of coating after 10 days, and c is the fingernail photo that is coated with after 20 days.Being respectively the left side fingernail is experimental group, and the right side fingernail is matched group.
The specific embodiment
When suffering from fingernail or toenail disease, the poor growth of fingernail or toenail, treatment time prolongs thereupon, and described fingernail or toenail disease can be enumerated tinea unguium, fingernail loses and supports disease or fingernail separation disease etc. as an example.When for example suffering from tinea unguium, the poor growth of fingernail or toenail is so generally need to take for a long time more than 6 months the antifungal of itraconazole (itraconazole) or fluconazol (fuluconazole) and so on.These medicines may cause hepatic injury and be unsuitable for taking for a long time.Therefore, the compositions that promotes the growth of fingernail or toenail is during with the antifungal coupling, is favourable from the aspect consideration that can shorten during the taking of antifungal.
Describe the present invention below in detail.
One aspect of the present invention has proved that salt that valproic acid or its pharmaceutically allow has the excellent effect that promotes fingernail or toenail growth, and provides and comprise it as fingernail or the toenail growth composition for promoting of effective ingredient.
As the effective ingredient of according to an aspect of the present invention compositions and valproic acid (the valproic acid that uses, 2-propylpentanoic acid) in epilepsy therapy, used as Anticonvulsants in the past, also manic depression was used as mood stabilizer (mood stabilizer).Known valproic acid is induced various kinds of cell reaction, but also can't know definitely by what mechanism and alleviate spasm and suppress Deviant Behavior.
According to an aspect of the present invention, the salt that valproic acid or its pharmaceutically allow is not particularly limited, and for example can be sodium valproate (sodium valproate).
According to an aspect of the present invention, be benchmark with the composition total weight, the salt that valproic acid or its pharmaceutically allow can contain 0.5～30 weight %.According to a further aspect of the invention, be benchmark with the composition total weight, the salt that valproic acid or its pharmaceutically allow can contain 1.0～20 weight %.According to another aspect of the invention, be benchmark with the gross weight of compositions, the salt that valproic acid or its pharmaceutically allow can contain 3.0～10 weight %.Contain sometimes with above-mentioned weight %, not only be fit to show and to satisfy stability and the safety of compositions by expected effect of the present invention, also suitablely aspect cost performance contain with above-mentioned scope.Particularly, be benchmark with the gross weight of compositions, the salt that valproic acid or its pharmaceutically allow contains sometimes less than 0.5 weight %, is difficult to expect the growth result of sufficient fingernail or toenail; Surpass 30 weight % and contain sometimes, the stability of compositions may reduce.
Above-mentioned composition according to an aspect of the present invention can be exterior-applied formulation.Above-mentioned composition according to a further aspect in the invention can be at specific part, for example wants to promote the local topical formulations that uses of fingernail or toenail position of growing.At this moment, can utilize with a spot of compositions desired location can real maximum efficiency topical remedy's transmission system (local drug dilivery system).
An aspect of of the present present invention provides a kind of pharmaceutical composition, wherein, contains and comprises valproic acid or its salt that pharmaceutically allows as the compositions of effective ingredient.Particularly, described pharmaceutical composition can promote to suffer from the patient's finger first of fingernail or toenail disease or the growth of toenail.Described fingernail or toenail disease comprise that tinea unguium, fingernail lose foster disease or fingernail separates disease.
Described pharmaceutical composition can also comprise antiseptic, stabilizing agent, wettable powder or emulsifying promoter, be used for pharmacy adjuvant such as salt that osmotic pressure regulates and/or buffer agent and useful material is gone up in other treatments, but turns to the form of multiple oral administration agent or non-oral administration agent by the usual way dosage form.Particularly, described pharmaceutical composition can use with the external dosage form.
Described oral administration agent has for example tablet, pill, hard and soft balsam wafer, liquor, suspensoid, emulsifying agent, syrup, powder, powder, microgranule, granule, pellet (pellet) etc., and these dosage forms can also contain surfactant, diluent (for example: lactose, glucose, sucrose, mannitol, sorbitol, cellulose or glycine), lubrication prescription (for example: silicon dioxide, Talcum, stearic acid and magnesium salt thereof or calcium salt or Polyethylene Glycol) except effective ingredient.Tablet can also comprise the bonding agent of aluminium-magnesium silicate, gelatinized corn starch, gelatin, Tragacanth, methylcellulose, sodium carboxymethyl cellulose or polyvinylpyrrolidine and so on, can also contain the pharmacy additives such as disintegrating agent, absorbent, coloring agent, flavouring agent or sweeting agent of starch, agar, alginic acid or its sodium salt and so on as required.Described tablet can be by common mixing, granulating or coating process manufacturing.
Described non-oral administration agent can be dosage forms such as injection, some drop, ointment, emulsion, gel, frost, spraying, suspensoid, Emulsion, suppository, patch for example, but is not limited thereto.
Described according to an embodiment of the invention pharmaceutical composition can pass through per os, non-per os for example rectum, part, percutaneous, intravenous, intramuscular, intraperitoneal, administration such as subcutaneous.
In addition, the pharmaceutically admissible consumption of described effective ingredient, namely dosage can be according to the order of severity, route of administration or the prescriptionist's of age for the treatment of target, sex, body weight, the specified disease that needs treatment or pathological state, disease or pathological state judgement difference.Dosage based on these factors can both be decided by those skilled in the art.Common dosage is 0.01mg/kg/ day～2000mg/kg/ day, preferred 1mg/kg/ day～100mg/kg/ day, but above-mentioned dosage not delimit the scope of the invention.
One aspect of the present invention provides a kind of cosmetic composition, wherein, contains and comprises valproic acid or its salt that pharmaceutically allows as the compositions of effective ingredient.
Described cosmetic composition for example can be cosmetics, and the profile of cosmetics can comprise medium or the substrate of cosmetic conduct and learning or Dermatology permission.This is to provide to be suitable for local all dosage forms of using, for example, solution, gel, solid, the anhydrous product of pulpous state, aqueous phase disperse to disperse in emulsion that oil phase obtains, the oil phase emulsion, complex emulsions, suspension, microemulsion, microcapsule, subparticle ball, ion-type (liposome) and nonionic folliculus dispersion, the foam (foam) that water obtains or the aerosol composition form that contains compressed propellant.These compositionss can be by those skilled in the art by the usual way manufacturing.
Cosmetic composition can also comprise fatty material, organic solvent, concentrating agents, gelating agent, softening agent, antioxidant, suspensoid, stabilizing agent, foaming agent (foaming agent), aromatic, surfactant, water, ion-type or nonionic emulsifier, filler, metal ion chelation agent, chelating agen, preservative agent, vitamin, blocker, wetting agent, essential oil, dyestuff, pigment, hydrophilic or lipophile activating agent, the normally used auxiliary agent of lipid folliculus or cosmetics or Dermatology field.Described auxiliary agent imports with the normally used amount of cosmetic conduct and learning or Dermatology field.
Described cosmetic composition does not limit dosage form especially, can suitably select dosage form as required.For example, can be fabricated to more than one the dosage form that is selected from astringent, emulsion, elite, frost, ointment, colloidal sol, facial film, patch, spray, powder, screening flaw rod, hands or foot emulsion, hands or foot frost, hands or foot oil, hands or foot elite, hands or foot lotion, cleansing cream, cleaning emulsion, cleaning foam and the clean water, but be not limited thereto.
Reach experimental example by the following examples and further describe formation of the present invention and effect.But following examples and experimental example only are to provide with illustrative purpose in order to help to understand the present invention, and category of the present invention and scope do not limit thus.
The manufacturing of [embodiment] sodium valproate solution
According to the composition of following table 1, comprise the solution of sodium valproate as embodiment by the usual way manufacturing.
[table 1]
| Composition | Content |
| HPMC?K100MC | 1.0 |
| Purified water | 79.2 |
| Sodium valproate | 8.3 |
| Ethanol | 10.0 |
| Polysorbas20 (Tween20) | 1.0 |
| BHT | 0.5 |
| Add up to | 100 |
[experimental example] fingernail growth result is estimated
With the embodiment solution (experimental group) of above-mentioned manufacturing and identical with other compositions of embodiment but with purified water replace the solution (matched group) of sodium valproate be coated on respectively on the left of and right side little finger fingernail, with Wound healing and bone regeneration with the (left side: experimental group, the right side: matched group) of going to bed behind the dressing membrane parcel.Experimental session is implemented coating with interval once a day.Measure before the coating, coating is after 10 days and be coated with the growth length of fingernail after 20 days, take a picture.The photograph result analyzes with image J software.Its result is shown in Fig. 1 and Fig. 2.Fig. 1 is expression coating after 10 days and be coated with the chart of the length of the growth of fingernail after 20 days, and Fig. 2 is (b) and be coated with the photo of the degree of the growth of (c) fingernail after 20 days after (a) before the expression coating, coating 10 days.
As shown in Figures 1 and 2, can confirm that experimental group compares the matched group fingernail, extent of growth is big.That is, sodium valproate has the effect that promotes the fingernail growth.Can confirm among Fig. 1 and Fig. 2 that particularly As time goes on, the fingernail growth result that sodium valproate causes increases.
Below the dosage form example of compositions of the present invention is described, but also can be applied as other various dosage forms, it only is used for specifying the present invention, does not limit the present invention.
[dosage form example 1] frost
[table 2]
| Gradation composition | Content (weight %) |
| Sodium valproate | 5.0 |
| Glycerol | 3.0 |
| Butanediol | 3.0 |
| Liquid paraffin | 7.0 |
| Beta glucan | 7.0 |
| Carbomer | 0.1 |
| Caprylic/capric triglyceride | 3.0 |
| Squalane | 5.0 |
| The cetearyl glucoside | 1.5 |
| Sorbitan stearate | 0.4 |
| |
1.2 |
| Triethanolamine | 0.1 |
| Antiseptic, pigment, spice | In right amount |
| Purified water | Surplus |
[dosage form example 2] ointment
[table 3]
| Composition | Weight % |
| Caprylic/capric triglyceride | 10 |
| Liquid Paraffin | 10 |
| Sorbitan sesquioleate | 6 |
| Octyl dodecanol polyethers-25 | 9 |
| The spermol ethylhexoate | 10 |
| Squalane | 1 |
| Salicylic acid | 1 |
| Glycerol | 15 |
| Sorbitol | 1 |
| Sodium valproate | 2 |
| Antiseptic, pigment, spice | In right amount |
| Purified water | Surplus |
[dosage form example 3] liquor
Sodium valproate ... ... ... ... ... ... ... .100mg
Isomerized sugar ... ... ... ... ... ... ... ... .10g
Mannitol ... ... ... ... ... ... ... ... ..5g
Vitamin C ... ... ... ... ... ... ... ... 50mg
Serine ... ... ... ... ... ... ... ... .50mg
Oils and fats ... ... ... ... ... ... ... .... an amount of
Purified water ... ... ... ... ... ... ... .... surplus
According to common liquor manufacture method, in purified water, add each composition dissolving, add an amount of NINGMENGXIANG after, mentioned component being mixed, add purified water then, is 100ml with adding integrally-regulated after the purified water, be filled into then in the brown bottle, sterilize, thereby make liquor.
Claims (7)
1. a fingernail or toenail growth composition for promoting wherein, comprises valproic acid or its salt that pharmaceutically allows as effective ingredient.
Fingernail according to claim 1 or toenail the growth composition for promoting, wherein, the salt that valproic acid or its pharmaceutically allow is sodium valproate.
3. fingernail according to claim 1 or toenail growth composition for promoting wherein, is benchmark with the composition total weight, and the salt that valproic acid or its pharmaceutically allow is 0.5～30 weight %.
Fingernail according to claim 1 or toenail the growth composition for promoting, wherein, described compositions is exterior-applied formulation.
5. a pharmaceutical composition wherein, contains each described fingernail or toenail growth composition for promoting in the claim 1～4.
6. pharmaceutical composition according to claim 5, wherein, described pharmaceutical composition is patient's finger first or the toenail growth composition for promoting of suffering from fingernail or toenail disease.
7. a cosmetic composition wherein, contains each described fingernail or toenail growth composition for promoting in the claim 1～4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2010-0097376 | 2010-10-06 | ||
| KR1020100097376A KR101733189B1 (en) | 2010-10-06 | 2010-10-06 | Composition for promotion of growing nail or toenail |
| PCT/KR2011/007352 WO2012047007A2 (en) | 2010-10-06 | 2011-10-05 | Composition for promoting fingernail or toenail growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103189041A true CN103189041A (en) | 2013-07-03 |
| CN103189041B CN103189041B (en) | 2015-09-30 |
Family
ID=45928213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180053494.4A Active CN103189041B (en) | 2010-10-06 | 2011-10-05 | Fingernail or toenail growth composition for promoting |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR101733189B1 (en) |
| CN (1) | CN103189041B (en) |
| WO (1) | WO2012047007A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112888443A (en) * | 2018-08-01 | 2021-06-01 | 爱迪克斯-欧有限公司 | Injectable composition with prolonged duration of action for its use in the treatment of nail diseases and/or for accelerating nail growth |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102021734B1 (en) * | 2018-05-24 | 2019-09-16 | 김선희 | Correcting method for ingrowing nail and protective coating agent used the method |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL72381A (en) | 1983-07-20 | 1988-03-31 | Sanofi Sa | Pharmaceutical composition based on valproic acid |
| KR100851955B1 (en) * | 2000-08-17 | 2008-08-12 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 | Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders |
| EP1293205A1 (en) | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| EP1839656A1 (en) | 2006-03-31 | 2007-10-03 | TopoTarget Germany AG | Use of valproic acid for the topical treatment of mild to moderate acne vulgaris |
-
2010
- 2010-10-06 KR KR1020100097376A patent/KR101733189B1/en active IP Right Grant
-
2011
- 2011-10-05 CN CN201180053494.4A patent/CN103189041B/en active Active
- 2011-10-05 WO PCT/KR2011/007352 patent/WO2012047007A2/en active Application Filing
Non-Patent Citations (2)
| Title |
|---|
| FERAH ARMUTCU ET.AL.: "《Effect of Long-Term Therapy with Sodium Valproate on Nail and Sodium Trace Element Status in Epileptic Children》", 《BIOLOGICAL TRACE ELEMENT RESEARCH》 * |
| 陆小左 等: "《看甲知健康》", 31 August 2009 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112888443A (en) * | 2018-08-01 | 2021-06-01 | 爱迪克斯-欧有限公司 | Injectable composition with prolonged duration of action for its use in the treatment of nail diseases and/or for accelerating nail growth |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120035691A (en) | 2012-04-16 |
| KR101733189B1 (en) | 2017-05-08 |
| WO2012047007A3 (en) | 2012-07-05 |
| CN103189041B (en) | 2015-09-30 |
| WO2012047007A2 (en) | 2012-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006326388B2 (en) | Compositions and methods for treating dermatological conditions | |
| US20070292461A1 (en) | Oleaginous pharmaceutical and cosmetic foam | |
| US9549905B2 (en) | Treatment of inflammatory and infectious skin disorders | |
| KR20190022476A (en) | Composition for topical application of compounds | |
| JP2013521300A (en) | Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds | |
| JP5859981B2 (en) | Carrier composition | |
| KR101330889B1 (en) | Composition for prevention of losing hair or promotion of growing hair | |
| CN102639127A (en) | Composition for skin improvement comprising hexamidines and retinoids | |
| US20200297614A1 (en) | Systems and methods for treating and/or preventing acne | |
| CN103189041B (en) | Fingernail or toenail growth composition for promoting | |
| JP2019081755A (en) | Composition | |
| RU2496476C1 (en) | External therapeutic agent for patients suffering atopic dermatitis | |
| WO2010094452A2 (en) | Novel composition | |
| US8143238B2 (en) | Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin D compound | |
| JP2017509705A (en) | Compositions for the treatment of skin diseases and disorders | |
| JP2018021027A (en) | Pharmaceutical preparation containing loxoprofen | |
| RU2573976C2 (en) | Use of benzyl benzoate for new purpose as antimycotic agent, producing and using antimycotic pharmaceutical compositions | |
| CN107530253B (en) | Composition containing psoralen for promoting hair growth and/or hair growth | |
| RU2517520C1 (en) | External therapeutic agent for patients suffering from atopic dermatitis | |
| KR20230076874A (en) | Composition for preventing, ameliorating or treating rosacea comprising isochlorogenic acid or salts thereof as an active ingredient | |
| US11045494B2 (en) | Use of potassium hydroxide in the treatment of actinic keratosis | |
| KR20160026042A (en) | A composition for anti-stress or homeostasis containing lactobionic acid | |
| WO2018191601A1 (en) | Stable pharmaceutical compositions comprising desonide | |
| US9889126B2 (en) | Use of naratriptan in the treatment of rosacea | |
| WO2021116808A1 (en) | Topical skin care composition and methods for treating eczema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |